Officials are planning to study Mapp Biopharmaceutical's MBP134 and Gilead Sciences' remdesivir, whi...
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief
Officials are planning to study Mapp Biopharmaceutical's MBP134 and Gilead Sciences' remdesivir, which saw widespread use against COVID-19.
Author: Fierce Biotech
Read Original Article